Number of the records: 1  

Circulating tumor cell-derived preclinical models: current status and future perspectives

  1. 1.
    0574949 - BFÚ 2024 RIV DE eng J - Journal Article
    Kahounová, Zuzana - Pícková, Markéta - Drápela, Stanislav - Bouchal, J. - Szczyrbova, E. - Navrátil, J. - Souček, Karel
    Circulating tumor cell-derived preclinical models: current status and future perspectives.
    Cell Death & Disease. Roč. 14, č. 8 (2023), č. článku 530. ISSN 2041-4889. E-ISSN 2041-4889
    R&D Projects: GA ČR(CZ) GA20-22984S; GA MZd(CZ) NU21-08-00023
    Institutional support: RVO:68081707
    Keywords : METASTATIC BREAST-CANCER * EX-VIVO CULTURE * PERIPHERAL-BLOOD
    OECD category: Cell biology
    Impact factor: 9, year: 2022
    Method of publishing: Open access
    https://www.nature.com/articles/s41419-023-06059-6

    Despite the advancements made in the diagnosis and treatment of cancer, the stages associated with metastasis remain largely incurable and represent the primary cause of cancer-related deaths. The dissemination of cancer is facilitated by circulating tumor cells (CTCs), which originate from the primary tumor or metastatic sites and enter the bloodstream, subsequently spreading to distant parts of the body. CTCs have garnered significant attention in research due to their accessibility in peripheral blood, despite their low abundance. They are being extensively studied to gain a deeper understanding of the mechanisms underlying cancer dissemination and to identify effective therapeutic strategies for advanced stages of the disease. Therefore, substantial efforts have been directed towards establishing and characterizing relevant experimental models derived from CTCs, aiming to provide relevant tools for research. In this review, we provide an overview of recent progress in the establishment of preclinical CTC-derived models, such as CTC-derived xenografts (CDX) and cell cultures, which show promise for the study of CTCs. We discuss the advantages and limitations of these models and conclude by summarizing the potential future use of CTCs and CTC-derived models in cancer treatment decisions and their utility as precision medicine tools.
    Permanent Link: https://hdl.handle.net/11104/0350472

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.